Drug · CHEMBL692
GLYCERIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. GLYCERIN. Drugs and targets, record CHEMBL692. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL692
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Glycerin component of monoctanoin d, Glycerin component of procalamine, Glycogelatin, Keybells, Nirolex, Senokot direct relief, Tixylix baby, Tixylix toddler, Waterhouse
- ChEMBL
- Other names
- E-422, E422, FEMA NO. 2525, Glicerol, Glycerin,anhydrous, Glycerinum, Glycerol, Glycerol 85%, Glycerolum, INS NO.422, INS-422, M 314429, NSC-9230, PZN 7474853, Tryhydroxypropane
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases14
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 14Source Open Targets
See all 14 diseasesTrials34
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 5 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00514852 | Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye | 316 | 2009-12-15 | glycerin | Its name | ClinicalTrials.gov | |
| NCT01010282 | Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects | 288 | 2011-12-13 | glycerin | Its name | ClinicalTrials.gov | |
| NCT01084148 | Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis | Phase 3 | 237 | 2014-03-18 | glycerol | Its name | ClinicalTrials.gov |
| NCT02280473 | A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease | Phase 3 | 188 | 2017-06-07 | glycerin | Its name | ClinicalTrials.gov |
| NCT03197922 | Treatment of Encopresis in Children With Autism Spectrum Disorders | Phase 3 | 117 | 2024-01-31 | glycerin | Its name | ClinicalTrials.gov |
| NCT01746511 | Glycerin Suppositories to Reduce Jaundice in Premature Infants | 79 | 2015-12-09 | glycerin | Its name | ClinicalTrials.gov | |
| NCT00938704 | Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms | Phase 4 | 71 | 2011-10-31 | glycerin | Its name | ClinicalTrials.gov |
| NCT02833415 | Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging | Phase 4 | 40 | 2019-05-02 | glycerol | Its name | ClinicalTrials.gov |
| NCT00786487 | Training Effects on Skeletal Muscle Fatty Acid Metabolism | 33 | 2015-07-23 | glycerol | Its name | ClinicalTrials.gov | |
| NCT02383758 | An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders | 22 | 2018-01-11 | glycerin | Its name | ClinicalTrials.gov |
1 to 10 of 34
See all 34 trialsComparisons in its trials21
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Carboxymethylcellulose and Glycerin Based Artificial Tear vs Carboxymethylcellulose Based Artificial Tear: serious adverse events | 1 of 157 | 1 of 159 | 316 | NCT00514852 | Trial comparisons |
| V0034CR01B vs V0034 CR 01B Vehicle: Treatment Response of Xerosis | 71 of 118 | 48 of 117 | 235 | NCT01084148 | Trial comparisons |
| V0034CR01B vs V0034 CR 01B Vehicle: serious adverse events | 16 of 118 | 19 of 117 | 235 | NCT01084148 | Trial comparisons |
| Refresh Optive® Gel Drops vs REFRESH LIQUIGEL®: serious adverse events | 0 of 94 | 1 of 94 | 188 | NCT02280473 | Trial comparisons |
| Glycerin Suppository vs No Glycerin Suppository: serious adverse events | 0 of 40 | 0 of 39 | 79 | NCT01746511 | Trial comparisons |
| Carboxymethylcellulose 0.5%, Glycerin 0.9% vs Sodium Hyaluronate 0.18%: serious adverse events | 0 of 33 | 0 of 37 | 70 | NCT00938704 | Trial comparisons |
| Empagliflozin vs Placebo: deaths from any cause | 0 of 20 | 0 of 20 | 40 | NCT02833415 | Trial comparisons |
| Empagliflozin vs Placebo: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT02833415 | Trial comparisons |
| New Formulation of Glycerin 1% Eye Drop vs Propylene Glycol and PEG 400 Eye Drop: serious adverse events | 0 of 16 | 0 of 16 | 32 | NCT00681265 | Trial comparisons |
| Treatment Program vs Waitlist Control: deaths from any cause | 0 of 10 | 0 of 10 | 20 | NCT02383758 | Trial comparisons |
1 to 10 of 21
See all 21 comparisons in its trialsPapers from its trials7
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL692
GET https://conductscience.org/api/drugs/v1/CHEMBL692/trials?page=2